Gilteritinib in FLT3-mutated acute myeloid leukemia: A real-world Italian experience.

In the cohort of 46 patients who received gilteritinib for relapse after transplantation, those who acquired the FLT3 mutation had a trend toward worse prognosis, although this did not reach statistical significance ( p = .064).

also in 111,027 other papers

However, patients with FLT3 mutations detected at diagnosis showed a trend toward inferior outcomes, although the difference was not statistically significant ( p = .064).

also in 53,322 other papers